Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950385 | 0.89 | CYP1A2 (0.50) | ACE2CYP1A2ALDH1A1GRM1ALOX15 | |
| SCHEMBL1446639 | 0.84 | ACE2 (0.47) | ACE2CYP1A2ALDH1A1GRM1FABP3 | |
| SCHEMBL1583816 | 0.84 | GRM1 (0.49) | ACE2CYP1A2ALDH1A1GRM1FABP3 | |
| SCHEMBL31044053 | 0.82 | GRM1 (0.47) | ACE2CYP1A2ALDH1A1GRM1FABP3 | |
| SCHEMBL16466774 | 0.82 | LMNA (0.45) | ACE2CYP1A2ALDH1A1ALOX15MAPT | |
| SCHEMBL8011592 | 0.82 | IRAK4 (0.38) | ACE2ALDH1A1GRM1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL9117656 | 0.80 | LMNA (0.43) | ACE2CYP1A2ALDH1A1ALOX15MAPT | |
| SCHEMBL28916218 | 0.79 | FABP3 (0.44) | ACE2ALDH1A1FABP3FABP4EIF4A3 | |
| SCHEMBL6838116 | 0.79 | SELL (0.48) | ACE2CYP1A2ALDH1A1GRM1ALOX15 | |
| SCHEMBL7253507 | 0.78 | ACE2 (0.43) | ACE2CYP1A2ALDH1A1FABP4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107056587-A | A kind of method of synthesis L menthols | 福建青松股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| EP-2649100-A1 | CELLULOSE SUBSTRATES, COMPOSITIONS AND METHODS FOR STORAGE AND ANALYSIS OF BIOLOGICAL MATERIALS | General Electric Company (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078104-A1 | CELLULOSE SUBSTRATES, COMPOSITIONS AND METHODS FOR STORAGE AND ANALYSIS OF BIOLOGICAL MATERIALS | GENERAL ELECTRIC COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
| JP-2010163420-A | HERBICIDAL COMPOSITION | ZENKOKU NOGYO KYODO KUMIAI RENGOKAI | 2010-07-29 | — | — | JP | disclosed |
| US-7511178-B2 | Hydroformylation of aqueous formaldehyde in the presence of a coordination catalyst preferably comprising rhodium dicarbonyl acetonylacetone and 2-phospha-2-icosyl-1,3,5,7-tetramethyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decane; hydrogenation of glycolaldehyde; catalyst selectivity; cost efficiency | SHELL OIL COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090012333-A1 | Hydroformylation of aqueous formaldehyde in the presence of a coordination catalyst preferably comprising rhodium dicarbonyl acetonylacetone and 2-phospha-2-icosyl-1,3,5,7-tetramethyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decane; hydrogenating glycolaldehyde; catalyst selectivity; cost efficiency | ALMEIDA LENERO KARINA QUETZALY | 2009-01-08 | — | — | US | disclosed |
| US-7449607-B2 | reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst comprising: a source of rhodium, and a ligand including a phospha-1,3,5,7-tetralkyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decyl group | SHELL OIL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070249871-A1 | reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst comprising: a source of rhodium, and a ligand including a phospha-1,3,5,7-tetralkyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decyl group | SHELL OIL COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1697291-A1 | PROCESS FOR PREPARING GLYCOLALDEHYDE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058788-A1 | PROCESS OF PREPARING GLYCOLALDEHYDE | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2005-06-30 | — | — | WO | disclosed |
| US-20050014954-A1 | Pyrrole synthesis | CIBA SPECIALTY CHEMICALS CORP. | 2005-01-20 | — | — | US | disclosed |
| EP-1451179-A1 | PYRROLE SYNTHESIS | Ciba SC Holding AG (CH) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003044011-A1 | PYRROLE SYNTHESIS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012333-A1 | Hydroformylation of aqueous formaldehyde in the presence of a coordination catalyst preferably comprising rhodium dicarbonyl acetonylacetone and 2-phospha-2-icosyl-1,3,5,7-tetramethyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decane; hydrogenating glycolaldehyde; catalyst selectivity; cost efficiency | H1-0, H1-2, H1-10 | ACE2 4337/4885CYP1A2 1206/4885ALDH1A1 117/4885 |
| US-20050014954-A1 | Pyrrole synthesis | PNPO, PPOX, DHPS | ACE2 1729/4885CYP1A2 64/4885ALDH1A1 511/4885 |
| US-20070249871-A1 | reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst comprising: a source of rhodium, and a ligand including a phospha-1,3,5,7-tetralkyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decyl group | PHOSPHO1, H1-2, H1-0 | ACE2 4651/4885CYP1A2 1135/4885ALDH1A1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.